4月27日,新一代cAMP偏向型GLP-1受体激动剂埃诺格鲁肽注射液(先维盈)在北京大学人民医院与复旦大学附属中山医院同步开出全国首批处方,标志着这款创新体重管理疗法正式在中国迈入临床应用阶段。 据悉,GLP-1受体激动剂的创新研发有两条路线。传统路线是以GLP-1为核心靶点叠加其他作用靶点,如GIP、GCG等。埃诺格鲁肽的偏向型信号传导机制,源自G蛋白偶联受体(GPCR)结构与功能。 ...
Source Link4月27日,新一代cAMP偏向型GLP-1受体激动剂埃诺格鲁肽注射液(先维盈)在北京大学人民医院与复旦大学附属中山医院同步开出全国首批处方,标志着这款创新体重管理疗法正式在中国迈入临床应用阶段。 据悉,GLP-1受体激动剂的创新研发有两条路线。传统路线是以GLP-1为核心靶点叠加其他作用靶点,如GIP、GCG等。埃诺格鲁肽的偏向型信号传导机制,源自G蛋白偶联受体(GPCR)结构与功能。 ...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.